Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Erik Digman Wiklund | Chief Executive Officer | 2.6M | -- | -- |
| Dr. Lubor Gaal Ph.D. | CFO & Head of BD | 2.88M | -- | 1968 |
| Mr. Ola Melin | Chief Operating Officer | 1.97M | -- | -- |
| Dr. Thomas Birkballe Hansen | Chief Technology Officer | 1.97M | -- | -- |
| Dr. Victor Levitsky M.D., Ph.D. | Chief Scientific Officer | 790k | -- | -- |
| Mr. Jon Amund Eriksen M.Sc., MSc | Special Advisor | 1.86M | -- | -- |
| Prof. Gustav Gaudernack Ph.D. | Chief Scientific Adviser | -- | -- | -- |
| Dr. Peter Skorpil Ph.D. | Vice President of Business Development | 1.07M | -- | -- |
Circio Holding ASA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec into lipid nanoparticles. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. The company was incorporated in 2010 and is based in Oslo, Norway.
Corporate Governance
Upcoming Events
April 10, 2025 at 5:00 AM UTC
Circio Holding ASA Earnings Date
Recent Events
Recent Events Information Not Available